The key driver is the relationship between elimination half-life and dosing interval. When the interval is short relative to the time required to eliminate the drug, more of the preceding dose remains when the next dose arrives, increasing subsequent concentrations. A longer interval allows more elimination and therefore produces less accumulation.
The increase becomes progressively smaller as repeated doses approach steady state. Early doses contribute both new drug and residual drug from prior doses, but the residual contribution eventually balances the amount eliminated between doses. This pattern helps clinicians anticipate that measured concentrations may change during treatment before settling into a stable exposure range.
Half-life and dosing interval should be considered together, not separately. A drug with a longer half-life retains more of each dose over a given interval, whereas extending the interval permits greater elimination before the next dose. Consequently, the same dosing interval can produce different accumulation factors for drugs with different half-lives.
To use the measure clinically, compare exposure during repeated dosing with exposure after a single dose, then interpret the result in light of the planned interval and the drug’s half-life. This approach connects the numerical factor to the dosing schedule and indicates whether repeated administration is likely to produce substantially higher concentrations or exposure.
Accumulation factor helps interpret both trough and peak concentrations during therapy. Residual drug raises later concentrations, so the lowest concentration before a dose and the highest concentration after dosing may differ from values observed after an isolated dose. Reviewing these patterns supports selection or evaluation of a dose interval intended to achieve stable exposure.
Clinical concern increases when accumulation raises concentrations or exposure beyond the intended range. By relating the factor to half-life and dosing interval, clinicians can anticipate how much exposure may build and how long treatment may take to approach stable levels. That information supports assessment of potential toxicity during repeated dosing.